#USA #NASDAQ #Cambridge #biotechnology #NeuroSense

NeuroSense Therapeutics Faces Compliance Notifications from Nasdaq

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN), a clinical biotechnology firm specializing in treatments for severe neurodegenerative diseases, has recently found itself facing challenges regarding its compliance with Nasdaq's listing requirements. A communication from Nasdaq's Listing Qualifications Department, dated April 2, 2026, notified the company about its non-compliance with two critical benchmarks.

Notification Details

The first notification cited that NeuroSense's ordinary shares had failed to maintain a minimum bid price of $1.00 per share for a consecutive period of 30 business days. This had been a requirement set forth by Nasdaq under Rule 5550(a)(2). The second notification addressed the company's market value of listed securities (MVLS), which fell below the mandated threshold of $35 million, a condition outlined under Rule 5550(b)(2).

Both notifications have raised significant concern but do not immediately affect the trading or listing status of NeuroSense's securities on the Nasdaq Capital Market. The company's common shares and associated warrants will continue to trade under the symbols “NRSN” and “NRSNW.”

Compliance Period and Company Strategy

NeuroSense has been afforded a compliance period of 180 days, extending to September 29, 2026, to correct the violations. To regain compliance, the company's shares must sustain a closing bid price of at least $1.00 for a minimum of ten consecutive business days, alongside achieving an MVLS of $35 million or more under Nasdaq's oversight.

In response to these challenges, NeuroSense is actively assessing various strategies to enhance shareholder value and achieve compliance. The company remains committed to monitoring its share price and MVLS closely, highlighting a strategic intent focused on sustaining long-term benefits for its investors.

About NeuroSense Therapeutics

NeuroSense is recognized in the biotechnology sector for its dedication to developing innovative therapeutic options for debilitating neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). As these afflictions present critical unmet medical needs, NeuroSense aims to pioneer combined therapies that target multiple biological pathways linked to these disorders.

The complexity of treating neurodegenerative diseases drives NeuroSense's ambition for comprehensive treatment strategies, which leverage extensive scientific research on various biomarkers. This forward-thinking approach to therapy development is instrumental in positioning NeuroSense as a key player in the biotechnology landscape.

For additional information, the company invites stakeholders to visit its official website and engage with its social media channels for up-to-date announcements and developments. As the situation evolves, NeuroSense remains committed to transparency regarding its operational and financial journey.

Conclusion

While NeuroSense Therapeutics navigates the current compliance challenges posed by Nasdaq notifications, its strategic focus on regaining compliance and enhancing market value underscores the company’s commitment to its stakeholders. The proactive measures being put in place reflect a broader vision to solidify its position in addressing the pressing healthcare needs related to neurodegenerative diseases, thus contributing to the overall growth and stability of the company.